Quantitative Analysis of Complex Drug-Drug Interactions Between Repaglinide and Cyclosporin A/Gemfibrozil Using Physiologically Based Pharmacokinetic Models With In Vitro Transporter/Enzyme Inhibition Data.
暂无分享,去创建一个
Yuichi Sugiyama | Kota Toshimoto | Y. Sugiyama | Soo-Jin Kim | S. Kim | K. Toshimoto | T. Yoshikado | Yoshiaki Yao | Yoshiaki Yao | Takashi Yoshikado | Takashi Yoshikado | Kota Toshimoto
[1] Yuichi Sugiyama,et al. Virtual Clinical Studies to Examine the Probability Distribution of the AUC at Target Tissues Using Physiologically-Based Pharmacokinetic Modeling: Application to Analyses of the Effect of Genetic Polymorphism of Enzymes and Transporters on Irinotecan Induced Side Effects , 2017, Pharmaceutical Research.
[2] M. Hirano,et al. INTERACTION BETWEEN FIBRATES AND STATINS - METABOLIC INTERACTIONS WITH GEMFIBROZIL , 2003, Drug metabolism and drug interactions.
[3] M. Niemi,et al. Gemfibrozil Is a Strong Inactivator of CYP2C8 in Very Small Multiple Doses , 2012, Clinical pharmacology and therapeutics.
[4] Kazuya Maeda,et al. Clarification of the Mechanism of Clopidogrel-Mediated Drug–Drug Interaction in a Clinical Cassette Small-dose Study and Its Prediction Based on In Vitro Information , 2016, Drug Metabolism and Disposition.
[5] P. Neuvonen,et al. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide , 2003, Diabetologia.
[6] L. Wienkers,et al. Selection of Alternative CYP3A4 Probe Substrates for Clinical Drug Interaction Studies Using In Vitro Data and In Vivo Simulation , 2010, Drug Metabolism and Disposition.
[7] Kazuya Maeda,et al. Physiologically Based Pharmacokinetic Modeling to Predict Transporter-Mediated Clearance and Distribution of Pravastatin in Humans , 2009, Journal of Pharmacology and Experimental Therapeutics.
[8] A. D. Rodrigues,et al. Quantitative Rationalization of Gemfibrozil Drug Interactions: Consideration of Transporters-Enzyme Interplay and the Role of Circulating Metabolite Gemfibrozil 1-O-β-Glucuronide , 2015, Drug Metabolism and Disposition.
[9] Akihiko Konagaya,et al. Estimation of feasible solution space using Cluster Newton Method: application to pharmacokinetic analysis of irinotecan with physiologically-based pharmacokinetic models , 2013, BMC Systems Biology.
[10] P. Neuvonen,et al. Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide , 2006, Clinical pharmacology and therapeutics.
[11] A. Y. Lu,et al. Inhibition and Induction of Cytochrome P450 and the Clinical Implications , 1998, Clinical pharmacokinetics.
[12] K. Maeda,et al. Investigation of the Impact of Substrate Selection on In Vitro Organic Anion Transporting Polypeptide 1B1 Inhibition Profiles for the Prediction of Drug-Drug Interactions , 2015, Drug Metabolism and Disposition.
[13] H. Kamimura,et al. The UDP-Glucuronosyltransferase 2B7 Isozyme Is Responsible for Gemfibrozil Glucuronidation in the Human Liver , 2007, Drug Metabolism and Disposition.
[14] Yuichi Sugiyama,et al. Analysis of the Repaglinide Concentration Increase Produced by Gemfibrozil and Itraconazole Based on the Inhibition of the Hepatic Uptake Transporter and Metabolic Enzymes , 2013, Drug Metabolism and Disposition.
[15] Kiyomi Ito,et al. Estimation of the Contribution of CYP2C8 and CYP3A4 in Repaglinide Metabolism by Human Liver Microsomes Under Various Buffer Conditions. , 2017, Journal of pharmaceutical sciences.
[16] Y. Sugiyama,et al. Gemfibrozil and Its Glucuronide Inhibit the Organic Anion Transporting Polypeptide 2 (OATP2/OATP1B1:SLC21A6)-Mediated Hepatic Uptake and CYP2C8-Mediated Metabolism of Cerivastatin: Analysis of the Mechanism of the Clinically Relevant Drug-Drug Interaction between Cerivastatin and Gemfibrozil , 2004, Journal of Pharmacology and Experimental Therapeutics.
[17] P. Neuvonen,et al. Glucuronidation Converts Clopidogrel to a Strong Time‐Dependent Inhibitor of CYP2C8: A Phase II Metabolite as a Perpetrator of Drug–Drug Interactions , 2014, Clinical pharmacology and therapeutics.
[18] P. Neuvonen,et al. Cyclosporine markedly raises the plasma concentrations of repaglinide , 2005, Clinical pharmacology and therapeutics.
[19] T. Goosen,et al. Mechanistic Modeling to Predict the Transporter- and Enzyme-Mediated Drug-Drug Interactions of Repaglinide , 2013, Pharmaceutical Research.
[20] Kiyomi Ito,et al. Effect of buffer conditions on CYP2C8-mediated paclitaxel 6α-hydroxylation and CYP3A4-mediated triazolam α- and 4-hydroxylation by human liver microsomes , 2016, Xenobiotica; the fate of foreign compounds in biological systems.
[21] I. Bjørnsdottir,et al. CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide. , 2003, British journal of clinical pharmacology.
[22] P. Neuvonen,et al. The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide , 2001, Clinical pharmacology and therapeutics.
[23] P. Neuvonen,et al. Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin. , 2005, Basic & clinical pharmacology & toxicology.
[24] Y. Lai,et al. Hepatic Disposition of Gemfibrozil and Its Major Metabolite Gemfibrozil 1-O-β-Glucuronide. , 2015, Molecular pharmaceutics.
[25] Toshihiko Ikeda,et al. The Quantitative Prediction of CYP-mediated Drug Interaction by Physiologically Based Pharmacokinetic Modeling , 2008, Pharmaceutical Research.
[26] L Fritsche,et al. Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine‐treated kidney transplant recipients , 1999, Clinical pharmacology and therapeutics.
[27] K. Maeda,et al. Transporter‐Mediated Drug–Drug Interactions Involving OATP Substrates: Predictions Based on In Vitro Inhibition Studies , 2012, Clinical pharmacology and therapeutics.
[28] A. Galetin,et al. A Comprehensive Assessment of Repaglinide Metabolic Pathways: Impact of Choice of In Vitro System and Relative Enzyme Contribution to In Vitro Clearance , 2012, Drug Metabolism and Disposition.
[29] Akihiko Konagaya,et al. Cluster Newton Method for Sampling Multiple Solutions of Underdetermined Inverse Problems: Application to a Parameter Identification Problem in Pharmacokinetics , 2014, SIAM J. Sci. Comput..
[30] P. Neuvonen,et al. Mechanism‐Based Inactivation of CYP2C8 by Gemfibrozil Occurs Rapidly in Humans , 2011, Clinical pharmacology and therapeutics.
[31] M. Rowland,et al. Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. , 2006, Journal of pharmaceutical sciences.
[32] M. Niemi,et al. Membrane transporters in drug development , 2010, Nature Reviews Drug Discovery.
[33] Yuichi Sugiyama,et al. Application of physiologically based pharmacokinetic modeling and clearance concept to drugs showing transporter-mediated distribution and clearance in humans , 2010, Journal of Pharmacokinetics and Pharmacodynamics.
[34] M Rowland,et al. Physiologically based pharmacokinetics of cyclosporine A: extension to tissue distribution kinetics in rats and scale-up to human. , 1998, The Journal of pharmacology and experimental therapeutics.
[35] P. Neuvonen,et al. The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects. , 2004, British journal of clinical pharmacology.
[36] Y. Sugiyama,et al. Analysis of Nonlinear and Nonsteady State Hepatic Extraction with the Dispersion Model Using the Finite Difference Method , 1998, Journal of Pharmacokinetics and Biopharmaceutics.
[37] K. Maeda,et al. Quantitative Analyses of Hepatic OATP‐Mediated Interactions Between Statins and Inhibitors Using PBPK Modeling With a Parameter Optimization Method , 2016, Clinical pharmacology and therapeutics.